Supercharged T-Cells take on melanoma in early trial
NCT ID NCT01955460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether giving patients with advanced melanoma immune cells that have been genetically modified to resist tumor-suppressing signals can help fight the cancer. The modified T-cells are given along with high-dose Interleukin-2, a drug that boosts immune activity. The study involves 34 patients and focuses on safety and whether the modified cells can be successfully produced and administered.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified T-cells (TGF-beta resistant) plus aldesleukin (high-dose Interleukin-2)
- What this could lead to
- If successful, this approach could point toward a more effective treatment for advanced melanoma by making immune cells resistant to tumor-suppressing signals.
- What could go wrong
- This is a very early phase 1 trial with only 34 participants, so it is primarily testing safety and feasibility. The modified T-cells may not work as expected, and high-dose IL-2 can cause severe side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Could a common heart drug boost immunotherapy against melanoma?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers